Navigation Links
Avanir Pharmaceuticals Announces Positive Results of Phase III,Study for Zenvia in Diabetic Neuropathic Pain

and approved by the U.S. Food and Drug Administration (FDA) through a special protocol assessment (SPA). The Company expects this to be the first of two pivotal studies required for the approval of Zenvia in the treatment of diabetic neuropathic pain.

About Zenvia

Zenvia is a combination of two well-characterized compounds, the active ingredient dextromethorphan, and the enzyme inhibitor quinidine, which serves to increase the bioavailability of dextromethorphan. The first-in-class drug candidate is believed to help regulate excitatory neurotransmission in two ways, through pre-synaptic inhibition of glutamate release via sigma-1 receptor agonist activity, and through postsynaptic glutamate response modulation via uncompetitive, low-affinity NMDA antagonist activity. Zenvia is currently in development for the treatment of Involuntary Emotional Expression Disorder (IEED) and diabetic neuropathic pain.

In October 2006, the Company received an approvable letter for the treatment of Zenvia in IEED. To address safety concerns raised in the FDA's approvable letter for Zenvia for the treatment of IEED, the company intends to initiate a confirmatory phase III study with a new lower quinidine dose formulation of Zenvia. The Company is considering whether it would be necessary or advisable to study a similar lower dose of quinidine in the second phase III trial being planned for diabetic neuropathic pain.

About Avanir

Avanir Pharmaceuticals is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. Avanir's products and product candidates address therapeutic markets that include the central nervous system, inflammation and infectious diseases. Avanir currently markets FazaClo(R), the only orally-disintegrating formulation of clozapine for the management of severely ill schizophrenic patients who fail to respond adequately to standard schizophrenic drug treatments. FazaClo is als
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Avanir Pharmaceuticals Presents IEED Prevalence and Updated Zenvia Long-Term Safety Data at AAN Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors of innovative ... protect their most important business assets, intellectual property ... Because of the highly-competitive nature of ... of the most litigious industry sectors of cases ...
(Date:1/15/2014)... Jan. 15, 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was promoted from ... has overseen the company,s four facilities in Massachusetts ... Mr. King joined Tegra Medical in 2012 with 20+ years ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Incorporated,(Nasdaq: VICL ) today announced the receipt ... from AnGes MG, Inc., under a previously announced,collaborative ... Phase 3 metastatic melanoma trial. Through a series ... $15.3 million to date,of the $22.6 million total ...
... vaccine induced neutralizing antibodies against widely divergent ... Baxter International,Inc. (NYSE: BAX ) announced publication ... England Journal of Medicine (NEJM) of data demonstrating ... I/II trial,endpoints for safety and immunogenicity (generating a ...
Cached Medicine Technology:Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 2Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 3Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 4The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 2The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 3The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 4The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 5
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... Scientists have identified the first genetic variant specifically ... sub-type accounting for around 10-15 per cent of ... study of the breast cancer sub-type, called invasive ... genetic causes of this particular kind of breast ... The research, published today (Thursday) in the journal ...
(Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
(Date:4/17/2014)... 2014) Two recent papers by a University ... may help scientists develop treatments or vaccines for ... encephalitis and other disease-causing flaviviruses. , Jeffrey S. ... genetics at the School of Medicine and an ... Institute, and colleagues recently published articles in the ...
(Date:4/17/2014)... synthetic biology team has created a new technology ... that could travel the body and selectively target ... cell-based, biological devices that monitor and modify human ... biology. However, no existing technology enabled bioengineers to ... state and respond in a customized fashion. , ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2
... RANCHO CORDOVA, Calif., March 9 ... program announced it helped the 500,000th child since ... almost $100 million in free eyecare and eyewear ... http://www.newscom.com/cgi-bin/prnh/20090309/SF80394 )Sight for Students started as ...
... Usage Trends and Growing Uninsured Population Raise Concerns ... Report from HealthLeaders-InterStudy NASHVILLE, Tenn., March 9 ... market intelligence, reports that through the first three ... health insurers saw on average a 25 percent ...
... with therapy if subjects are willing and motivatedANN ARBOR, Mich., ... raised in an upper-middle class suburb, she felt a deep ... basement where she rode her Big Wheel at age 3 ... 8.As years went by, the home,s empty spaces disappeared, replaced ...
... Nu Skin Presents Findings at Asian Societies of Cosmetic ... a newly identified internal free radical generator, age-related NOX ... (NYSE: NUS ) links the enzyme to ... The research was presented at the 9th Scientific Conference ...
... Philanthropist and Renowned Chef Art Smith Creates Oat-Inspired Menu ... In Times Square today, Quaker announces ... purpose movement powered by Quaker and the human energy ... lives every day with the wholesome goodness of whole-grain ...
... wireless customer relationship management (CRM) experts, today ... and compliance software solution. iComply helps companies ... email for improved compliance with government regulations, ... The software is offered with a Lotus ...
Cached Medicine News:Health News:VSP's Sight for Students Program Helps 500,000th Child 2Health News:VSP's Sight for Students Program Helps 500,000th Child 3Health News:Florida Emergency Room Costs Increased 25 Percent in the Last Year and May Lead to More Opportunity for Pharma Industry 2Health News:Florida Emergency Room Costs Increased 25 Percent in the Last Year and May Lead to More Opportunity for Pharma Industry 3Health News:Compulsive Hoarding Poses Safety and Psychological Risks 2Health News:Compulsive Hoarding Poses Safety and Psychological Risks 3Health News:Study Links Internal Source of Aging and Skin Damage 2Health News:Study Links Internal Source of Aging and Skin Damage 3Health News:Quaker Oats and Share Our Strength Announce New Movement to Fight Childhood Hunger 2Health News:Quaker Oats and Share Our Strength Announce New Movement to Fight Childhood Hunger 3Health News:Quaker Oats and Share Our Strength Announce New Movement to Fight Childhood Hunger 4Health News:Quaker Oats and Share Our Strength Announce New Movement to Fight Childhood Hunger 5Health News:iEnterprises Launches iComply, Lotus Notes Email Archiving and Compliance Software 2Health News:iEnterprises Launches iComply, Lotus Notes Email Archiving and Compliance Software 3
... Peg electrodes typically are positioned ... enable epidural recording of brain ... and are furnished in several ... thicknesses. A 4.6 mm twist ...
... cortical strip electrodes are extra thin ... through a burr hole. The narrow ... enables quick and secure attachment to ... Integra Epilepsy electrode designs, they are ...
... John R. Gates and Mary E. Dunn ... are designed for reliability, safety and ease ... electrodes, platinum contacts are mounted flush with ... have larger exposures. Strip and depth electrodes ...
Integra Epilepsy grid electrodes are thin and flexible for easier placement and to conform to the curvature of the cortical surface. Lead tunneling is done using a 14-gauge tunneling needle (ET-2)....
Medicine Products: